Introduction to Bipolar Disorder and Comorbid Conditions (Case &
Comment)
Incorporating Clinical Trial Data Into Bipolar Disorder Management (Case &
Comment)To obtain credit, study the material and complete the CME Posttest and Evaluation as instructed at the end of each activity.
After completing each of these educational activities, you should be able to achieve the objective given in the activity.
Patients with bipolar disorder are likely to present with a variety of symptoms and comorbidities, and children and elderly patients with bipolar disorder require special consideration. Bipolar depression can lower quality of life and substantially impair functioning. However, misdiagnosis of bipolar disorder is very likely because patients frequently fail to report manic episodes as periods of illness, which can often lead to a misdiagnosis of unipolar depression and the use of an incorrect, ineffective, and potentially harmful treatment strategy. These activities were designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on bipolar disorder. There are no prerequisites for participating in this activity.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates each Brief Report educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™ and each Case and Comment educational activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest (i.e., any proprietary entity producing health care goods or services consumed by, or used on, patients) occurring within the 12 months prior to joining this activity. The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows:
Dr. Calabrese, Chair, has received federal funding from the U.S. Department of Defense, the Health Resources Services Administration, and the National Institute of Mental Health; has received research or grants from the Cleveland foundation, National Alliance for Research on Schizophrenia and Depression, Repligen, the Stanley Medical Research Institute, Abbott, AstraZeneca, GlaxoSmithKline, Janssen, and Eli Lilly; is a member of the advisory boards for Abbott, AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, and Solvay/Wyeth; and has received honoraria from AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, and Solvay/Wyeth. [article list]
Dr. Gentil, Chair, is a consultant for Servier, Wyeth, and Eli Lilly; and is a member of the speakers/advisory boards for Wyeth and Pfizer. [article list]
Dr. Ketter, Chair, is a consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Jazz, Novartis, Solvay, and Wyeth; has received grant/research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Pfizer, Repligen, and Wyeth; has received lecture honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline; and his spouse, Nzeera Ketter, M.D., is an employee of Johnson & Johnson. [article list]
Dr. Chang is a consultant for Abbott, AstraZeneca, GlaxoSmithKline, Eli Lilly, and Shire; has received grant/research support from Abbott, AstraZeneca, GlaxoSmithKline, Eli Lilly, and Otsuka; and is a member of the speakers bureaus for Abbott, AstraZeneca, and Eli Lilly. [article list]
Dr. Fagiolini is a consultant for Pfizer and Bristol-Myers Squibb; has received honoraria from Pfizer, Bristol-Myers Squibb, and Novartis; and is a member of the speakers/advisory boards for Pfizer, Bristol-Myers Squibb, and Eli Lilly (Italy). [article list]
Dr. Friedman has received grant/research support from Bristol-Myers Squibb, Pfizer, AstraZeneca, Novartis, Sanofi-Avantis, Cyberonics, National Institute of Mental Health, and Wyeth; has received honoraria from Medscape LLC; is a member of the speakers/advisory boards for AstraZeneca and Pfizer; and is a stock shareholder of Cephalon. [article list]
Dr. Nierenberg has received research support from Bristol-Myers Squibb, Cederroth, Cyberonics, Forest, Eli Lilly, GlaxoSmithKline, Janssen, Lichtwer Pharma, the National Alliance for Research on Schizophrenia and Depression, the National Institute of Mental Health, Pfizer, the Stanley Foundation, and Wyeth-Ayerst; is a member of the speakers bureau for Bristol-Myers Squibb, Cyberonics, Forest, Eli Lilly, GlaxoSmithKline, and Wyeth-Ayerst; and is a member of the advisory board/is a consultant for Abbott, BrainCells Inc., Bristol-Myers Squibb, Cederroth, Eli Lilly, GlaxoSmithKline, Genaissance, Innapharma, Janssen, Novartis, Pfizer, Sepracor, Shire, and Somerset. [article list]
Dr. Simon is an emloyee of Group Health Cooperative. [article list]
Dr. Swartz has received grant/research support from and is a member of the speakers/advisory board for Bristol-Myers Squibb; and has received honoraria from AstraZeneca. [article list]
Dr. Vieta is a consultant for AstraZeneca, Bial, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Pfizer, Sanofi, and Servier; has received grant/research support from AstraZeneca, Bial, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi-Aventis, and Servier; and is a member of the speakers/advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi-Aventis, and Servier. [article list]
Dr. Young is an employee of the University of British Columbia, has received grant/research support from AstraZeneca, and has received honoraria from and is a member of the speakers/advisory boards for AstraZeneca, Eli Lilly, Janssen, and Sanofi-Aventis. [article list]
In these Brief Reports and Case and Comments,, investigational information about pharmaceutical agents may be presented that is outside U.S. Food and Drug Administration-approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. Please consult the paragraph titled “Disclosure of Off-Label Usage” at the end of each Brief Report and Case and Comments for a complete listing of off-label or investigational uses. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
These activities have undergone a 3-tier review process: (1) the entire faculty of the series discussed the content at a peer-review planning session; (2) the Chair reviewed the activities for accuracy and fair balance; and (3) a member of the External CME Advisory Board reviewed the activities to determine whether the material is evidence-based and objective.
These Brief Reports and Case and Comments are developed from the Seventh International Conference on Bipolar Disorder, which was held June 7–9, 2007, in Pittsburgh, Pa. These activities were independently developed by the CME Institute of Physicians Postgraduate Press, Inc., in conjunction with the International Conference on Bipolar Disorder, pursuant to educational grants from Eli Lilly and Company, Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc, and Pfizer Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporters.
 |
|
| - Chairs - Valentim Gentil, MD, PhD Joseph R. Calabrese, MD Terence A. Ketter, MD |
|
| Project Assistants | Anna M. Esquivel, MA Ariel A. Britton, MA E. Alice Leslie, BA Julie L. Hoffman, MFA Aaron Worcester, BA |
| Project Associates | Anna Acerra, BA Sally A. Elliott, BA Andrew J. Gienapp, BA |
| Project Manager | Kathryn Maceri, BA |
| Electronic Media Manager | F. Grant Whittle, PhD |
| Managing Director | Jane B. Eckstein, MA |
| Associate CME Director | Jennifer G. Alessi, MA |
| Assistant CME Director | Susan K. Beaton, BS |
| CME Editor | Becky Brown Derych, MA |
| CME Coordinator | Diane Brunner |
| External CME Advisory Board | |
Chair Michael H. Ebert, MD Vice Chair Richard C. Shelton, MD |
|
E. Sherwood Brown, PhD, MD Stephanie Cavanaugh, MD Lawrence J. Cohen, PharmD Larry Culpepper, MD, MPH John M. Downs, MD Alan J. Gelenberg, MD |
Paul King, MD Joseph A. Lieberman, III, MD Elizabeth H. B. Lin, MD Frank W. Ling, MD J. Sloan Manning, MD Meir Steiner, MD, PhD |
© 2007 Physicians Postgraduate Press, Inc. |
|
Psychiatrist.com Home
Keyword Search